These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 34987643)

  • 1. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
    Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
    Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic Advances in Breast Cancer in Nuclear Medicine.
    Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
    Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer.
    O'Brien SR; Mankoff DA
    Cancer J; 2024 May-Jun 01; 30(3):140-141. PubMed ID: 38753747
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted radionuclide therapy: frontiers in theranostics.
    Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects.
    Shah A; Dabhade A; Bharadia H; Parekh PS; Yadav MR; Chorawala MR
    Z Naturforsch C J Biosci; 2024 Sep; 79(9-10):235-266. PubMed ID: 38807355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic Surrogacy of [
    Kim SB; Lee MS; Song IH; Park HS; Kim SE
    Mol Pharm; 2023 Jul; 20(7):3460-3470. PubMed ID: 37294909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiopharmaceutical enhancement by drug delivery systems: A review.
    Kleynhans J; Grobler AF; Ebenhan T; Sathekge MM; Zeevaart JR
    J Control Release; 2018 Oct; 287():177-193. PubMed ID: 30086338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An introduction to the clinical practice of theranostics in oncology.
    Turner JH
    Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper radiopharmaceuticals for theranostic applications.
    Ahmedova A; Todorov B; Burdzhiev N; Goze C
    Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
    Notni J; Wester HJ
    J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.
    Turner JH
    Cancer Biother Radiopharm; 2019 Apr; 34(3):135-140. PubMed ID: 30973278
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
    Sgouros G; Dewaraja YK; Escorcia F; Graves SA; Hope TA; Iravani A; Pandit-Taskar N; Saboury B; James SS; Zanzonico PB
    J Nucl Med; 2021 Dec; 62(Suppl 3):12S-22S. PubMed ID: 34857617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostics and Patient-Specific Dosimetry.
    Bednarz B
    Semin Radiat Oncol; 2023 Jul; 33(3):317-326. PubMed ID: 37331786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies.
    Brosch-Lenz J; Yousefirizi F; Zukotynski K; Beauregard JM; Gaudet V; Saboury B; Rahmim A; Uribe C
    PET Clin; 2021 Oct; 16(4):627-641. PubMed ID: 34537133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
    Duan H; Iagaru A; Aparici CM
    Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.
    Li T; Ao ECI; Lambert B; Brans B; Vandenberghe S; Mok GSP
    Theranostics; 2017; 7(18):4551-4565. PubMed ID: 29158844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
    Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
    Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
    [No Abstract]   [Full Text] [Related]  

  • 19. Preclinical Pharmacokinetics and Dosimetry Studies of
    Marsh IR; Grudzinski J; Baiu DC; Besemer A; Hernandez R; Jeffery JJ; Weichert JP; Otto M; Bednarz BP
    J Nucl Med; 2019 Oct; 60(10):1414-1420. PubMed ID: 30926646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.